“Microbiome Therapeutics (formerly NuMe Health) is running two clinical trials of a microbiome modulator designed to enhance insulin sensitivity in patients with prediabetes, and lessen adverse GI effects in those who are taking the antidiabetic drug metformin. To carry the company through those trials, its investors, including BVM Capital, have provided $1.3 million in bridge financing. Microbiome Therapeutics completed a $1.5 million Series A last year.”

December 16, 2013 – Read it now in MedCity News